10-Q/A: Grace Therapeutics Amends 10-Q for Share Count Correction

Grace Therapeutics, Inc. filed an amended quarterly report (10-Q/A) to correct the reported number of outstanding common shares as of November 13, 2025.

Summary

• The filing is an Amendment No. 1 on Form 10-Q/A to the original Form 10-Q for the period ended September 30, 2025.
• The sole purpose of this amendment is to correct the number of shares of common stock outstanding on the cover page of the original filing.
• The correct number of outstanding shares of common stock as of November 13, 2025, is 15,474,026.
• No other changes have been made to the Original Filing, including no updates to reflect events occurring subsequent to the original filing date.
• New certifications by the principal executive officer and principal financial officer are included as exhibits, as required by Rule 12b-15 of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: The filing is a neutral technical amendment to correct an administrative detail regarding outstanding shares, with no impact on financial performance or operational outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance, as its purpose is solely to correct an administrative detail in a previously filed report.

Management Comments

• "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."

Industry Context

This amendment is a technical correction to an administrative detail and does not provide any information related to broader industry trends, competitive landscape, or the company's position within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: Minimal direct impact, as the amendment corrects an administrative detail rather than substantive financial or operational information. It ensures accuracy of public records.

Key Dates

Recommendation

The filing is a technical amendment to correct the number of outstanding common shares and does not provide any new financial or operational information that would warrant a change in investment recommendation. Investors should refer to the original 10-Q for substantive details regarding the company's performance and outlook.

Keywords

Grace Therapeutics, GRCE, 10-Q/A, amendment, common stock, outstanding shares, SEC filing, biotechnology, pharmaceuticals